These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 12745061

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome.
    Vega GL, Cater NB, Hadizadeh DR, Meguro S, Grundy SM.
    Clin Pharmacol Ther; 2003 Sep; 74(3):236-44. PubMed ID: 12966367
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Fenofibrate ameliorates diabetic and dyslipidemic profiles in KKAy mice partly via down-regulation of 11beta-HSD1, PEPCK and DGAT2. Comparison of PPARalpha, PPARgamma, and liver x receptor agonists.
    Srivastava RA.
    Eur J Pharmacol; 2009 Apr 01; 607(1-3):258-63. PubMed ID: 19245804
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Lipase maturation factor 1: its expression in Zucker diabetic rats, and effects of metformin and fenofibrate.
    Forcheron F, Basset A, Del Carmine P, Beylot M.
    Diabetes Metab; 2009 Dec 01; 35(6):452-7. PubMed ID: 19854668
    [Abstract] [Full Text] [Related]

  • 9. Mechanisms of the triglyceride- and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients.
    Forcheron F, Cachefo A, Thevenon S, Pinteur C, Beylot M.
    Diabetes; 2002 Dec 01; 51(12):3486-91. PubMed ID: 12453904
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Antidyslipidemic potential of a novel farnesoid X receptor antagonist in a hamster model of dyslipidemia: Comparative studies of other nonstatin agents.
    Shinozawa E, Amano Y, Yamakawa H, Haba M, Shimada M, Tozawa R.
    Pharmacol Res Perspect; 2018 Apr 01; 6(2):e00390. PubMed ID: 29541476
    [Abstract] [Full Text] [Related]

  • 12. Effects of theabrownin from pu-erh tea on the metabolism of serum lipids in rats: mechanism of action.
    Gong J, Peng C, Chen T, Gao B, Zhou H.
    J Food Sci; 2010 Aug 01; 75(6):H182-9. PubMed ID: 20722930
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effects of fenofibrate on lipid parameters in obese rhesus monkeys.
    Winegar DA, Brown PJ, Wilkison WO, Lewis MC, Ott RJ, Tong WQ, Brown HR, Lehmann JM, Kliewer SA, Plunket KD, Way JM, Bodkin NL, Hansen BC.
    J Lipid Res; 2001 Oct 01; 42(10):1543-51. PubMed ID: 11590209
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Cholesterol-lowering effects and potential mechanisms of different polar extracts from Cyclocarya paliurus leave in hyperlipidemic mice.
    Jiang C, Wang Q, Wei Y, Yao N, Wu Z, Ma Y, Lin Z, Zhao M, Che C, Yao X, Zhang J, Yin Z.
    J Ethnopharmacol; 2015 Dec 24; 176():17-26. PubMed ID: 26477373
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Preventive effects of fenofibrate on insulin resistance, hyperglycaemia, visceral fat accumulation in NIH mice induced by small-dose streptozotocin and lard.
    Xie W, Nie Y, Du L, Zhang Y, Cai G.
    Pharmacol Res; 2007 May 24; 55(5):392-9. PubMed ID: 17306985
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.